How well have diagnostic tests and therapies for gout been evaluated?

Current Opinion in Orthopaedics

Volumn 11, Issue 1, 2000, Pages 71-76

  Schlesinger, Naomi ^a   Baker, Daniel G ^b   Schumacher Jr , H Ralph ^b  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; BENZBROMARONE; COLCHICINE; CORTICOSTEROID; CORTICOTROPIN; INDOMETACIN; NONSTEROID ANTIINFLAMMATORY AGENT; URIC ACID;

BONE MARROW SUPPRESSION; DIAGNOSTIC TEST; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFICACY; DRUG SAFETY; EVALUATION; GASTROINTESTINAL SYMPTOM; GOUT; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MEASUREMENT; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; URINALYSIS;

EID: 0033984265     PISSN: 10419918     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001433-200002000-00013     Document Type: Review

References (48)

1. 1 McCarty DJ, Hollander JL. Identification of urate crystals in gouty synovial fluid. Ann Intern Med 1961, 54:452-460.
2. 2 Weinberger A, Schumacher HR, Agudelo CA: Urate crystals in asymptomatic metatarsophalangeal joints. Ann Intern Med 1979, 92:56-57.
3. 3 Bomalaski JS, Lluberas G, Schumacher HR, Jr.: Monosodium urate crystals in the knee joints of patients with asymptomatic nontophaceous gout. Arthritis Rheum 1986, 29:1480-1484.
4. 4 Von Essen R, Holtta AMH, Pikkarainen R: Quality control of synovial fluid crystal identification. Ann Rheum Dis 1998, 57:107-109.
5. 5 Petrocelli A, Wong AL, Sweezy RL: Identification of pathologic synovial fluid crystals on Gram-stains. J Clin Rheumatol 1998, 4:103-105.
6. 6 Schumacher HR, Sieck MS, Rothfuss S, Clayburne GM, Baumgarten DF, Mochan BS, et al.: Reproducibility of synovial fluid analyses. Arthritis Rheum 1986, 29:770-774.
7. 7 Owen-Smith B, Quiney J, Read J: Salivary urate in gout, exercise, and diurnal variation [letter]. Lancet 1998, 351:1932.
8. 8 Kobayashi K, Morioka Y, Isaka Y, Tozawa T: Determination of uric acid in scalp hair for non-invasive evaluation of uricemic controls in hyperuricemia. Biol Pharm Bull 1998, 21:398-400.
9. 9 Schlesinger N, Baker DG, Schumacher HR, Jr: Serum uric acid during bouts of acute gouty arthritis. J Rheum 1997, 24:2265-2266.
10. 10 Logan JA, Morrison E, McGill PE: Serum uric acid in acute gout. Ann Rheum Dis 1997, 56:696-697.
11. 11 Wortmann RL: Effective treatment of gout: an analogy. Am J Med 1998, 105:513-514.
12. 12 Harris MD, Siegel LB, Alloway JA: Gout and hyperuricemia. Am Fam Physician 1999 15, 59:925-934.
13. 13 McDonald E, Marino C: Stopping progression to tophaceous gout. When and how to use urate-lowering therapy. Postgrad Med 1998, 104:117-127.
14. 14 Agudelo CA, Schumacher HR Jr, Phelps P: Effect of exercise on urate crystal-induced inflammation in canine joints. Arthritis Rheum 1972, 15:609-616.
15. 15 Schumacher HR Jr: Crystal induced arthritis: an overview. Am J Med 1996, 100(suppl):46-52.
16. 16 Schlesinger N, Baker DG, Beutler AM, Hoffman BI, Schumacher HR, Jr: Local ice therapy during bouts of acute gouty arthritis. Arthritis Rheum 1996, 39(suppl):S84.
17. 17 Dorwart BB, Hansell JR, Schumacher HR, Jr: Effects of cold and heat on urate-induced synovitis in dog. Arthritis Rheum 1974, 17:563-571.
18. 18 Shrestha M, Morgan DL, Moreden JM, Singh R, Nelson M, Hayes JE: Randomized double-blind comparison of the analgesic efficacy of intramuscular ketorolac and oral indomethacin in the treatment of acute gouty arthritis. Ann Emerg Med 1995, 26:682-686.
19. 19 Bellamy N, Gilbert JR, Brooks PM, Emmerson BT, Campbell J: A survey of current prescribing practices of anti-inflammatory and urate lowering drugs in gouty arthritis in the Province of Ontario. J Rheumatol 1988, 15:1841-1871.
20. 20 Rozenberg S, Lang T, Laatar A, Koeger AC, Orcel P, Bourgerois P: Diversity of opinions on the management of gout in France: a survey of 750 rheumatologists. Rev Rhum (Engl Ed) 1996, 63:255-261.
21. 21 Ben-Chetrit E, Levy M: Colchicine: 1998 update. Semin Arthritis Rheum 1998, 28:48-59.
22. 22 Ahbern MJ, Reid C, Gordon TP: Does colchicine work? Results of the first controlled study in gout. Austr N Z J Med 1987, 17:301-304.
23. 23 Paulus HE, Schlosstein LH, Godfrey RC, Klinenberg JR, Bluestone R: Prophylactic cołchicine therapy in intercritical gout: a placebo-controlled study of probenecid-treated patients. Arthritis Rheum 1987, 17:609-614.
24. 24 Wallace SL, Singer JZ: Review: systemic toxicity associated with the intravenous administration of colchicine - guidelines for use. J Rheumatol 1988, 15:495-499.
25. 25 Evans TI, Wheeler MT, Small RE, Breitbach SA, Sanders KM, Roberts WN: A comprehensive investigation of inpatient colchicine use shows more education is needed. J Rheumatol 1996, 23:143-148.
26. 26 Wałłace SL, Singer JZ: Review: systemic toxicity associated with the intravenous administration of colchicine - guidelines for use. J Rheumatol 1988, 15:495-499.
27. 27 Roberts WN, Liang MH, Stern SH: Colchicine and acute gout: reassessment of risks and benefits. JAMA 1987, 257:1920-1922.
28. 28 Gordon GV, Schumacher: Management of gout. Am Fam Physician 1969, 10:62-66.
29. 29 Gray RG, Tenenbaum J, Gottlieb NL: Local corticosteroid injection treatment in rheumatic disorders. Semin Arthritis Rheum 1979, 10:231-254.
30. 30 Groff GD, Franck WA, Raddatz DA: Systemic steroid therapy for acute gout: a clinical trial and review of the literature. Semin Arthritis Rheum 1990, 19:329-336.
31. 31 Alloway JA, Moriarty MJ, Hoogland YT, Nashel D: Comparison of triamcinolone acetonide with indomethacin in the treatment of acute gouty arthritis. J Rheumatol 1993, 20:111-113.
32. 32 Axelrod D, Preston S: Comparison of parenteral adrenocorticotropic hormone with oral indomethacin in the treatment of acute gout. Arthritis Rheum 1988, 31:803-805.
33. 33 Seigel LB, Alloway JA, Nashel DJ: Comparison of adrenocorticotropic hormone and triamcinolone acetonide in the treatment of gouty arthritis. J Rheumatol 1994, 21:1325-1327.
34. 34 Fam AG: Should patients with interval gout be treated with urate lowering drugs? [editorial] J Rheumatol 1995, 22:1621-1623.
35. 35 Ferraz MB: An evidence-based appraisal of the management of tophaceous interval gout. J Rheumatol 1995, 22:1618-1620.
36. 36 Ferraz MB, O'Brien B: A cost effectiveness analysis of urate lowering drugs in nontophaceous recurrent gouty arthritis. J Rheumatol 1995, 22:908-914.
37. 37 Yamanaka H, Togashi R, Hakoda M, Terai C, Kashiwazaki S, Dan T, Kamatani N: Optimal range of serum urate concentrations to minimize risk of gouty attacks during anti-hyperuricemic treatment. Adv Exp Med Biol 1998, 431:13-18.
38. 38 Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yu TF: Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977, 20:895-900.
39. 39 Bellamy N, Gilbert JR, Brooks PM, Emmerson BT, Campbell J: A survey of current prescribing practices of anti-inflammatory and urate lowering drugs in gouty arthritis in the Province of Ontario. J Rheumatol 1988, 15:1841-1871.
40. 40 Medellin MV, Erickson AR, Enzenauer RJ: Variability of treatment for gouty arthritis between rheumatologists and primary care physicians. JCR: J Clin Rheumatol 1997, 3:24-27.
41. 41 Pawlotsky Y: What is the optimal treatment for acute crystal induced arthritis? Rev Rheum 1996, 63:231-233.
42. 42 Perez-Ruiz F, Alonso-Ruiz A, Calaabozo M, Herrero-Beites A, Garcia-Erauskin G, Ruiz-Lucea E: Efficacy of allopurinol and benzbromarone for the control of hyperuricemia: a pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis 1998, 57:545-549.
43. 43 Perez-Ruiz F, Calaabozo M, Fernandez-Lopez J, Herrero-Beites A, Ruiz-Lucea E, Garcia-Erauskin G, Duruelo J, Alonso-Ruiz A: Treatment of chronic gout in patients with renal function impairment: an open, randomized, actively controlled study. J Clin Rheumatol 1999, 5:49-55.
44. 44 Weinberger A, Schreiber M, Sperling O, DeVeris A: Comparative evaluation of uricosuric and allopurinol treatment in a series of 183 patients gouty patients. Intern Rev Rheum 1975, 5:681.
45. 45 Rundles RW, Metz EN, Silberman HR: Allopurinol in the treatment of gout. Ann Intern Med 1966, 64:229-258.
46. 46 Beutler Am, Rull M, Schlesinger N, Baker DG, Hoffman BI, Schumacher HR, Jr: Allopurinol may have protective effect against acute gout attacks independently from its hypouricemic effect Arthritis Rheum 1996, 39(suppl):S85.
47. 47 Scott JT: Comparison of allopurinol to probenecid. Ann Rheum Dis 1966, 25:623-626.
48. 48 Nass JE, Sanders LJ: Chronic tophaceous gout in a patient with a history of allopurinol toxicity. Cutis 1998, 62:239-241.